0.81%
-7.82%
-9.94%
-17.32%
-62.55%
-92.34%
-92.29%
AI Spotlight on MLEC
Company Description
Moolec Science SA, a science-based ingredient company, focuses on producing animal proteins in plants through Molecular Farming, a disruptive technology in the alternative protein landscape.The company's product portfolio and pipeline leverage the agronomic efficiency of used target crops, such as soybeans and peas.It operates in the United States, Europe, and South America.
The company was founded in 2008 and is based in Luxembourg.
Market Data
| Last Price | 0.76 |
| Change Percentage | 0.81% |
| Open | 0.84 |
| Previous Close | 0.75 |
| Market Cap ( Millions) | 29 |
| Volume | 4080 |
| Year High | 3.25 |
| Year Low | 0.7 |
| M A 50 | 0.84 |
| M A 200 | 0.98 |
Financial Ratios
| FCF Yield | -33.12% |
| Dividend Yield | 0.00% |
| ROE | -100.75% |
| Debt / Equity | 215.40% |
| Net Debt / EBIDTA | -143.75% |
| Price To Book | 4.19 |
| Price Earnings Ratio | -3.91 |
| Price To FCF | -3.02 |
| Price To sales | 5.17 |
| EV / EBITDA | -5.94 |
News
- Oct -16 - Moolec Has Received USDA Approval for the First Genetically Modified Pea in History
- Oct -02 - Moolec Science (MLEC) Q4 2024 Earnings Call Transcript
- Oct -02 - Moolec Science Presents Fiscal Year 2024 Annual Business Update
- Sep -25 - Moolec Science to Host Fourth Quarter Fiscal Year 2024 Business Update Conference Call
- Sep -13 - Moolec Received NASDAQ Bid Price Letter
- Sep -05 - Moolec Confirms US Harvest and Promising Yields for Plant-Grown Products GLASO(TM) and Piggy Sooy(TM) in October
- Jul -16 - Top 4 Risk Off Stocks You'll Regret Missing In July
- Jul -15 - Why Is Moolec Science (MLEC) Stock Down 18% Today?
- Jul -15 - Moolec Signs an Offtake Agreement With Major Global CPG Company to Hit the US Market in 2025
- Apr -30 - Moolec Announces New Patent Granting in the United States for Molecular Farming Platform
- Apr -22 - Why Is Moolec Science (MLEC) Stock Up 121% Today?
- Apr -22 - Moolec Becomes First Molecular Farming Company to Achieve USDA Approval for Plant-Grown Animal Proteins
- Mar -13 - Moolec Science Presents Second Quarter Fiscal Year 2024 Business Update
- Mar -06 - Moolec Science to Host Second Quarter Fiscal Year 2024 Business Update Conference Call
- Jan -11 - Down -18.03% in 4 Weeks, Here's Why You Should You Buy the Dip in Moolec Science SA (MLEC)
- Jan -11 - Why Is Moolec Science (MLEC) Stock Up 40% Today?
- Dec -14 - Moolec Science SA (MLEC) Q1 2024 Earnings Call Transcript
- Dec -14 - Moolec Science Presents First Quarter Fiscal Year 2024 Business Update
- Dec -07 - Moolec Science to Host First Quarter Fiscal Year 2024 Business Update Conference Call
- Oct -20 - Moolec Science Presents Fourth Quarter FY 2023 Business Update
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Science-based Food Ingredients
Expected Growth : 9.27 %
What the company do ?
Moolec Science SA's Science-based Food Ingredients use biotechnology to produce animal-derived proteins, like milk and egg proteins, through microbial fermentation, reducing environmental impact.
Why we expect these perspectives ?
Moolec Science SA's 9.27% growth in Science-based Food Ingredients is driven by increasing demand for sustainable and healthy food options, advancements in biotechnology, and rising consumer awareness of environmental impact. Additionally, growing investments in R&D, strategic partnerships, and expanding distribution channels contribute to the company's rapid growth.
Moolec Science Sa Products
| Product Range | What is it ? |
|---|---|
| Microbial-based protein production | Moolec Science SA uses microbial fermentation to produce high-quality protein ingredients for the food, feed, and pharmaceutical industries. |
| Cell-free protein expression | Moolec Science SA offers cell-free protein expression technology for the production of recombinant proteins, including enzymes, antibodies, and vaccines. |
| Microbial-based enzyme production | Moolec Science SA develops and produces microbial-based enzymes for various industries, including food, feed, and pharmaceuticals. |
| Biomanufacturing services | Moolec Science SA provides contract biomanufacturing services for the production of microbial-based products, including proteins, enzymes, and small molecules. |
| Research and development services | Moolec Science SA offers research and development services for the development of new microbial-based products and processes. |
Moolec Science SA's Porter Forces
Threat Of Substitutes
Moolec Science SA has a moderate threat of substitutes due to the presence of alternative products in the market, but the company's unique technology and high-quality products reduce the likelihood of customers switching to substitutes.
Bargaining Power Of Customers
Moolec Science SA has a low bargaining power of customers due to the company's strong brand reputation and high-quality products, which reduces the customers' ability to negotiate prices.
Bargaining Power Of Suppliers
Moolec Science SA has a moderate bargaining power of suppliers due to the presence of multiple suppliers in the market, but the company's long-term contracts and strong relationships with suppliers reduce the suppliers' bargaining power.
Threat Of New Entrants
Moolec Science SA has a high threat of new entrants due to the growing demand for biotechnology products and the relatively low barriers to entry in the industry, which increases the likelihood of new competitors entering the market.
Intensity Of Rivalry
Moolec Science SA operates in a highly competitive industry with several established players, which increases the intensity of rivalry and requires the company to continuously innovate and improve its products to maintain its market share.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 20.75% |
| Debt Cost | 3.95% |
| Equity Weight | 79.25% |
| Equity Cost | 1.49% |
| WACC | 2.00% |
| Leverage | 26.18% |
Moolec Science SA : Quality Control
Moolec Science SA passed 1 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| OXB.L | Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform … |
| AFMD | Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has … |
| IFRX | InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved … |
| SLGL | Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead … |
| EXAI | Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Oxford Biomedica
A-Score
1-Year Total Return ->
🥈
InflaRx
A-Score
1-Year Total Return ->
🥉
Moolec Science
A-Score
1-Year Total Return ->
4
Sol-Gel Technologies
A-Score
1-Year Total Return ->
5
Exscientia
A-Score
1-Year Total Return ->
6
